CC BY-NC-ND 4.0 · AJP Rep 2019; 09(04): e341-e345
DOI: 10.1055/s-0039-1694035
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Role of Maternal Thyroid-Stimulating Immunoglobulin in Graves' Disease for Predicting Perinatal Thyroid Dysfunction

1   Department of Obstetrics and Gynecology, Albany Medical Center, Albany, New York
,
Asha Rijhsinghani
1   Department of Obstetrics and Gynecology, Albany Medical Center, Albany, New York
2   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Fetal Diagnosis Unit, University of Iowa, Iowa City, Iowa
› Author Affiliations
Further Information

Publication History

17 February 2019

06 May 2019

Publication Date:
11 November 2019 (online)

Abstract

Objective To assess maternal thyroid-stimulating immunoglobulin (TSI) as a predictor of neonatal thyroid hyperthyroidism in pregnancies complicated by Graves' disease.

Methods This is a 10-year retrospective study of patients with a history of Graves' disease and elevated TSI activity level defined as 1.3 times the normal. All subjects underwent cordocentesis for ultrasound findings of suspected fetal thyrotoxicosis (fetal tachycardia, oligohydramnios, hydrops, and thyromegaly). Neonatal diagnosis was made based on neonatal thyroid function testing or symptoms.

Results Fourteen patients were included in the study, seven with active Graves' disease requiring antithyroid drug (“ATD group”) and seven with iatrogenic hypothyroidism on levothyroxine (“levothyroxine group”). Four cases (57%) of neonatal thyrotoxicosis were diagnosed in the levothyroxine group compared with two cases (28%) in the ATD group. The lowest maternal TSI level at which a neonate did not develop hyperthyroidism was 2.6 for the levothyroxine group and 2.5 for the ATD group. The odds ratio of a neonate from the levothyroxine group developing hyperthyroidism compared with one from the ATD group is 3.3 (95% confidence interval: 0.4–30.7).

Conclusion For patients with Graves' disease, those with iatrogenic hypothyroidism and TSI > 2.5 times the basal level are at the highest risk for neonatal thyrotoxicosis.

 
  • References

  • 1 Girling JC. Thyroid disorders in pregnancy. Obstetrics, Gynaecol Reprod Med 2008; 18 (10) 259-264
  • 2 Patil-Sisodia K, Mestman JH. Graves hyperthyroidism and pregnancy: a clinical update. Endocr Pract 2010; 16 (01) 118-129
  • 3 Burch HB, Cooper DS. Management of Graves disease: a review. JAMA 2015; 314 (23) 2544-2554
  • 4 Kriplani A, Buckshee K, Bhargava VL, Takkar D, Ammini AC. Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Biol 1994; 54 (03) 159-163
  • 5 Millar LK, Wing DA, Leung AS, Koonings PP, Montoro MN, Mestman JH. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol 1994; 84 (06) 946-949
  • 6 Mitsuda N, Tamaki H, Amino N, Hosono T, Miyai K, Tanizawa O. Risk factors for developmental disorders in infants born to women with Graves disease. Obstet Gynecol 1992; 80 (3 Pt 1): 359-364
  • 7 Polak M. Hyperthyroidism in early infancy: pathogenesis, clinical features and diagnosis with a focus on neonatal hyperthyroidism. Thyroid 1998; 8 (12) 1171-1177
  • 8 Polak M, Le Gac I, Vuillard E. , et al. Fetal and neonatal thyroid function in relation to maternal Graves' disease. Best Pract Res Clin Endocrinol Metab 2004; 18 (02) 289-302
  • 9 Daneman D, Howard NJ. Neonatal thyrotoxicosis: intellectual impairment and craniosynostosis in later years. J Pediatr 1980; 97 (02) 257-259
  • 10 McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid 1992; 2 (02) 155-159
  • 11 Hamada N, Momotani N, Ishikawa N. , et al. Persistent high TRAb values during pregnancy predict increased risk of neonatal hyperthyroidism following radioiodine therapy for refractory hyperthyroidism. Endocr J 2011; 58 (01) 55-58
  • 12 Alexander EK, Pearce EN, Brent GA. , et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017; 27 (03) 315-389
  • 13 Latif R, Morshed SA, Zaidi M, Davies TF. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am 2009; 38 (02) 319-341 , viii
  • 14 Thorpe-Beeston JG, Nicolaides KH, Felton CV, Butler J, McGregor AM. Maturation of the secretion of thyroid hormone and thyroid-stimulating hormone in the fetus. N Engl J Med 1991; 324 (08) 532-536
  • 15 Thyroid stimulating immunoglobulin. ARUP Laboratories. Available at: http://Itd.aruplab.com/test/pub/0099430 . Accessed March 24, 2018
  • 16 Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008; 158 (01) 69-75
  • 17 Zakarija M, McKenzie JM. Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab 1983; 57 (05) 1036-1040
  • 18 Levy-Shraga Y, Tamir-Hostovsky L, Boyko V, Lerner-Geva L, Pinhas-Hamiel O. Follow-up of newborns of mothers with Graves' disease. Thyroid 2014; 24 (06) 1032-1039
  • 19 van Dijk MM, Smits IH, Fliers E, Bisschop PH. Maternal thyrotropin receptor antibody concentration and the risk of fetal and neonatal thyrotoxicosis: a systematic review. Thyroid 2018; 28 (02) 257-264
  • 20 Clavel S, Madec AM, Bornet H, Deviller P, Stefanutti A, Orgiazzi J. Anti TSH-receptor antibodies in pregnant patients with autoimmune thyroid disorder. Br J Obstet Gynaecol 1990; 97 (11) 1003-1008
  • 21 Barbesino G, Tomer Y. Clinical review: clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 2013; 98 (06) 2247-2255
  • 22 Bjørgaas MR, Farstad H, Christiansen SC, Blaas HG. Impact of thyrotropin receptor antibody levels on fetal development in two successive pregnancies in a woman with Graves' disease. Horm Res Paediatr 2013; 79 (01) 39-43
  • 23 Momotani N, Noh JY, Ishikawa N, Ito K. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab 1997; 82 (11) 3633-3636
  • 24 Duncombe GJ, Dickinson JE. Fetal thyrotoxicosis after maternal thyroidectomy. Aust N Z J Obstet Gynaecol 2001; 41 (02) 224-227
  • 25 Zakarija M, McKenzie JM, Hoffman WH. Prediction and therapy of intrauterine and late-onset neonatal hyperthyroidism. J Clin Endocrinol Metab 1986; 62 (02) 368-371
  • 26 Volumenie JL, Polak M, Guibourdenche J. , et al. Management of fetal thyroid goitres: a report of 11 cases in a single perinatal unit. Prenat Diagn 2000; 20 (10) 799-806
  • 27 Aslam M, Inayat M. Fetal and neonatal Graves disease: a case report and review of the literature. South Med J 2008; 101 (08) 840-841
  • 28 Nachum Z, Rakover Y, Weiner E, Shalev E. Graves' disease in pregnancy: prospective evaluation of a selective invasive treatment protocol. Am J Obstet Gynecol 2003; 189 (01) 159-165